A Phase 2 Open Label Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma Pretreated With One immunochecKPOint INhibiTor (Anti PD1/PDL1): the BREAKPOINT Trial
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms BREAKPOINT
- 13 Mar 2019 According to the trial design presented at the 2019 Genitourinary Cancers Symposium, to date, 2 pts have been enrolled.
- 16 Feb 2019 Trial design presented at the 2019 Genitourinary Cancers Symposium
- 25 Jun 2018 Status changed from not yet recruiting to recruiting.